The U.S. has purchased $3.2 billion worth of the new omicron-targeted boosters that became fully authorized Sept. 9, but those funds were taken from a budget previously marked for COVID-19 treatments and tests, Dr. Gounder and Dr. Rosenthal wrote. At-home COVID-19 tests are no longer offered for free because of dwindling funds, and the nation is expected to run out of free vaccines by January.
Pfizer’s and Moderna’s next-generation vaccines, which clinical trials proved effective but never required human trials, could be a hint that “the pharmaceutical industry may be moving into more familiar territory,” the physicians wrote.
Now, drugmakers could be “developing products that may be a smidgen better than what came before, selling — sometimes overselling — their increased effectiveness in the absence of adequate controlled studies or published data, advertising them as desirable for all when only some stand to benefit significantly, and in all likelihood raising the price later,” they said.
Dr. Gounder and Dr. Rosenthal acknowledged the high efficacy rates of the omicron-focused boosters but said “salesmanship trumps science” once a product has a marketing campaign behind it.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.